Biogen's Zinbryta Gets EU Nod – But Where Will It Fit In?

Biogen and AbbVie Inc.'s multiple sclerosis therapy, Zinbryta (daclizumab), has been given a green light for use in Europe – but what gap can this new drug fill in a crowded therapy space?